Know Cancer

forgot password

HO11414: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Phase 2
18 Years
Not Enrolling
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

Thank you

Trial Information

HO11414: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Inclusion Criteria:

1. Histologically confirmed CLL/SLL.

2. No prior cytotoxic chemotherapy for their disease; prior therapy with single-agent
rituximab is permitted.

3. Understand and voluntarily sign an informed consent document.

4. At least 18 years at the time of signing the informed consent document.

5. In cases of SLL, subjects must have at least one bidimensionally measurable lesion at
least ≥1.5 cm measured in one dimension.

6. ECOG performance status of less than or equal to 2 at study entry

7. Laboratory test results within these ranges:

- Absolute neutrophil count greater than or equal to 1500/μL

- Platelet count greater than or equal to 100,000/μL

- Subjects with neutrophils <1500/μL or platelets <100,000/μL with splenomegaly or
extensive bone marrow involvement as the etiology for their cytopenias are

- Subjects must have adequate renal function with a creatinine clearance of ≥40
mL/min as determined by the Cockcroft-Gault calculation

- Total bilirubin less than or equal to 2X upper limit laboratory normal (ULN);
subjects with non-clinically significant elevations of bilirubin due to
Gilbert's disease are not required to meet these criteria

- Serum transaminases AST (SGOT) and ALT (SGPT) less than or equal to 5X ULN

- Serum alkaline phosphatase ≤5X ULN

8. Disease-free of prior malignancies for ≥2 years with the exception of basal or
squamous cell skin carcinoma, carcinoma "in situ" of the breast or cervix, or
localized prostate cancer (treated definitively with hormone therapy, radiotherapy,
or surgery).

9. Life expectancy of at least 3 months.

10. All study participants must be willing to be registered into the mandatory RevAssist®
program, and be willing and able to comply with the requirements of RevAssist®.

11. Subjects must not have a known history of hypersensitivity to mannitol.

12. Prior therapy with rituximab is permitted, even in the setting of
rituximab-refractory disease.

13. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (subjects
intolerant to aspirin may use warfarin or low molecular weight heparin) if clinically

14. Females of childbearing potential (FCBP)† must have a negative serum or urine
pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again
within 24 hours prior to prescribing lenalidomide for Cycle 1 (prescriptions must be
filled within 7 days as required by RevAssist) and must either commit to continued
abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
control, one highly effective method and one additional effective method AT THE SAME
TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree
to ongoing pregnancy testing. Men must agree to use a latex condom during sexual
contact with a FCBP even if they have had a successful vasectomy. See Appendix:
Risks of Fetal Exposure, Pregnancy Testing Guidelines and Acceptable Birth Control

Exclusion Criteria:

1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the informed consent document or complying
with the protocol treatment.

2. Pregnant or breast-feeding females. Lactating females must agree not to breast-feed
while taking lenalidomide.

3. Any condition, including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study or confounds
the ability to interpret data from the study.

4. Subjects are not eligible if there is a prior history or current evidence of central
nervous system or leptomeningeal involvement.

5. Known hypersensitivity to thalidomide.

6. Concurrent use of other anti-cancer agents or treatments.

7. Known to be positive for HIV or infectious hepatitis (type B or C).

8. Prior malignancy, except for adequately treated basal cell or squamous cell skin
cancer, in situ cervical or breast cancer, or other cancer from which the subject has
been disease free for at least 2 years.

9. Severe or life-threatening anaphylaxis or hypersensitivity reaction when previously
exposed to rituximab or other monoclonal antibody therapy.

10. Chronic hepatitis B or hepatitis C infection.

11. New York Heart Association class 3-4 heart failure.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Time to progression

Outcome Description:

The primary objective is progression-free survival (PFS). Tumor measurements and disease assessments will be performed at the time of screening, following cycles 3 and 6 of induction chemotherapy, every 4 cycles during the maintenance portion of treatment, and at the end of treatment (EOT). Subjects with clinical evidence of progression prior to a planned disease assessment will be evaluated at the time of clinically suspected progression. Follow-up visits for disease assessment will occur every 3 months after the EOT visit until PD, initiation of alternate anti-neoplastic therapy, decision by the subject to withdraw from the study, or death. The follow-up period will begin after the EOT visit, and all subjects will be followed for at least 2 years after completion of therapy or until death or progression and until the last patient has been followed for at least 1 year following completion of therapy.

Outcome Time Frame:

Up to 30 months

Safety Issue:


Principal Investigator

Julie Chang, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Wisconsin, Madison


United States: Food and Drug Administration

Study ID:




Start Date:

July 2013

Completion Date:

December 2017

Related Keywords:

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • CLL
  • SLL
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma



University of WisconsinMadison,, Wisconsin  53792-5666